{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:15:52Z","timestamp":1784780152203,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by the TRF Research Career Development Grant under Grant number","award":["RSA6080020"],"award-info":[{"award-number":["RSA6080020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pimobendan, diuretics, and an angiotensin-converting enzyme inhibitor (ACEi) are widely used for the management of chronic valvular heart disease in dogs; however, the effects of that combination on heart rate variability (HRV) are unknown. The purpose of this study was to assess the HRV of symptomatic myxomatous mitral valve degeneration (MMVD) dogs in response to therapy with a combination of pimobendan, diuretics, and ACEi.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MMVD stage C (n\u2009=\u200917) dogs were enrolled and a 1-hour Holter recording together with echocardiography, blood pressure measurement, and blood chemistry profiles were obtained before and 1, 3, and 6 months after oral treatment with pimobendan (0.25\u00a0mg\/kg), enalapril (0.5\u00a0mg\/kg), and furosemide (2\u00a0mg\/kg) twice daily. The results revealed that MMVD stage C dogs at the baseline had lower values of time-domain indices, low frequency (LF), high frequency (HF), and total power, as well as higher value of LF\/HF. Triple therapy significantly increases these parameters in MMVD stage C dogs (P\u2009&lt;\u20090.05). A positive moderate correlation was observed between time domain parameters and a left ventricular internal diastole diameter normalized to body weight (P\u2009&lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>It can be concluded that MMVD stage C dogs possess low HRV due to either the withdrawal of parasympathetic tone or enhanced sympathetic activation, and a combination therapy was shown to enhance cardiac autonomic modulation inferred from the increased heart rate variability. Therefore, a combination therapy may be useful for restoring normal autonomic nervous system activity in dogs with MMVD stage C.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12917-023-03770-6","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T03:28:55Z","timestamp":1697081335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs"],"prefix":"10.1186","volume":"19","author":[{"given":"Prapawadee","family":"Pirintr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakkawee","family":"Saengklub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakit","family":"Boonpala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusak","family":"Kijtawornrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"issue":"5","key":"3770_CR1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/01.CIR.93.5.1043","volume":"93","author":"Heart rate variability","year":"1996","unstructured":"Heart rate variability.: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043\u201365.","journal-title":"Circulation"},{"issue":"1","key":"3770_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0167-5273(02)00207-3","volume":"87","author":"M Karcz","year":"2003","unstructured":"Karcz M, Chojnowska L, Zareba W, Ruzyllo W. Prognostic significance of heart rate variability in dilated cardiomyopathy. Int J Cardiol. 2003;87(1):75\u201381.","journal-title":"Int J Cardiol"},{"issue":"8","key":"3770_CR3","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1161\/01.CIR.0000117090.01718.2A","volume":"109","author":"AJ Camm","year":"2004","unstructured":"Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation. 2004;109(8):990\u20136.","journal-title":"Circulation"},{"issue":"2","key":"3770_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.18632\/aging.101386","volume":"10","author":"F Sessa","year":"2018","unstructured":"Sessa F, Anna V, Messina G, Cibelli G, Monda V, Marsala G, et al. Heart rate variability as predictive factor for sudden cardiac death. Aging. 2018;10(2):166\u201377.","journal-title":"Aging"},{"key":"3770_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/VHRM.S279322","volume":"17","author":"HCD Souza","year":"2021","unstructured":"Souza HCD, Philbois SV, Veiga AC, Aguilar BA. Heart Rate Variability and Cardiovascular Fitness: what we know so far. Vasc Health Risk Manag. 2021;17:701\u201311.","journal-title":"Vasc Health Risk Manag"},{"key":"3770_CR6","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.tvjl.2021.105704","volume":"274","author":"RA Baisan","year":"2021","unstructured":"Baisan RA, Vulpe V, Ohad DG. Short-term heart rate variability in healthy dogs and dogs in various stages of degenerative mitral valve disease evaluated before pharmacotherapy. Vet J. 2021;274:105704.","journal-title":"Vet J"},{"issue":"9","key":"3770_CR7","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1292\/jvms.17-0016","volume":"79","author":"P Pirintr","year":"2017","unstructured":"Pirintr P, Saengklub N, Limprasutr V, Sawangkoon S, Kijtawornrat A. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration. J Vet Med Sci. 2017;79(9):1480\u20138.","journal-title":"J Vet Med Sci"},{"issue":"2","key":"3770_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.rvsc.2014.01.006","volume":"96","author":"C Chompoosan","year":"2014","unstructured":"Chompoosan C, Buranakarl C, Chaiyabutr N, Chansaisakorn W. Decreased sympathetic tone after short-term treatment with enalapril in dogs with mild chronic mitral valve disease. Res Vet Sci. 2014;96(2):347\u201354.","journal-title":"Res Vet Sci"},{"issue":"3","key":"3770_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jvim.15488","volume":"33","author":"BW Keene","year":"2019","unstructured":"Keene BW, Atkins CE, Bonagura JD, Fox PR, Haggstrom J, Fuentes VL, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33(3):1127\u201340.","journal-title":"J Vet Intern Med"},{"key":"3770_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jvc.2021.11.003","volume":"39","author":"EF Bode","year":"2022","unstructured":"Bode EF, Mederska E, Hodgkiss-Geere H, Radford AD, Singleton DA. Analysis of canine cardiovascular therapeutic agent prescriptions using electronic health records in primary care veterinary practices in the United Kingdom. J Vet Cardiol. 2022;39:35\u201345.","journal-title":"J Vet Cardiol"},{"issue":"6","key":"3770_CR11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/jvim.15863","volume":"34","author":"G Wess","year":"2020","unstructured":"Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, et al. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: the VALVE trial. J Vet Intern Med. 2020;34(6):2232\u201341.","journal-title":"J Vet Intern Med"},{"issue":"5","key":"3770_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","volume":"22","author":"J Haggstrom","year":"2008","unstructured":"Haggstrom J, Boswood A, O\u2019Grady M, Jons O, Smith S, Swift S, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22(5):1124\u201335.","journal-title":"J Vet Intern Med"},{"issue":"11","key":"3770_CR13","first-page":"1219","volume":"52","author":"E de Madron","year":"2011","unstructured":"de Madron E, King JN, Strehlau G, White RV. Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. Can Vet J. 2011;52(11):1219\u201325.","journal-title":"Can Vet J"},{"key":"3770_CR14","doi-asserted-by":"publisher","first-page":"700230","DOI":"10.3389\/fvets.2021.700230","volume":"8","author":"N Saengklub","year":"2021","unstructured":"Saengklub N, Pirintr P, Nampimoon T, Kijtawornrat A, Chaiyabutr N. Short-term Effects of Sacubitril\/valsartan on echocardiographic parameters in Dogs with Symptomatic Myxomatous Mitral Valve Disease. Front Vet Sci. 2021;8:700230.","journal-title":"Front Vet Sci"},{"issue":"6","key":"3770_CR15","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1111\/jvim.14586","volume":"30","author":"A Boswood","year":"2016","unstructured":"Boswood A, Haggstrom J, Gordon SG, Wess G, Stepien RL, Oyama MA, et al. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: the EPIC Study-A Randomized Clinical Trial. J Vet Intern Med. 2016;30(6):1765\u201379.","journal-title":"J Vet Intern Med"},{"issue":"5","key":"3770_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","volume":"2","author":"NB Schiller","year":"1989","unstructured":"Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of Echocardiography Committee on Standards, Subcommittee on quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358\u201367.","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"3770_CR17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2460\/javma.1995.206.02.194","volume":"206","author":"JW Buchanan","year":"1995","unstructured":"Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc. 1995;206(2):194\u20139.","journal-title":"J Am Vet Med Assoc"},{"key":"3770_CR18","first-page":"21","volume-title":"Principles of electrocardiographic recording","author":"LP Tilley","year":"1992","unstructured":"Tilley LP. Essentials of Canine and Feline Electrocardiography: interpretation and treatment. In: Tilley LP, editor. Principles of electrocardiographic recording. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1992. pp. 21\u201339.","edition":"3"},{"issue":"6","key":"3770_CR19","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/jvim.15331","volume":"32","author":"MJ Acierno","year":"2018","unstructured":"Acierno MJ, Brown S, Coleman AE, Jepson RE, Papich M, Stepien RL, et al. ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018;32(6):1803\u201322.","journal-title":"J Vet Intern Med"},{"issue":"3","key":"3770_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1053\/j.ctsap.2005.05.006","volume":"20","author":"JP Petrie","year":"2005","unstructured":"Petrie JP. Practical application of holter monitoring in dogs and cats. Clin Tech Small Anim Pract. 2005;20(3):173\u201381.","journal-title":"Clin Tech Small Anim Pract"},{"issue":"5","key":"3770_CR21","first-page":"1","volume":"9","author":"VNK Dong","year":"2022","unstructured":"Dong VNK, Tantisuwat L, Setthawong P, Tharasanit T, Sutayatram S, Kijtawornrat A. The preliminary Chronic Effects of Electromagnetic Radiation from Mobile Phones on Heart Rate Variability, Cardiac function, blood profiles, and Semen Quality in Healthy Dogs. Vet Sci. 2022;9(5):1\u201315.","journal-title":"Vet Sci"},{"issue":"4","key":"3770_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11259-012-9531-0","volume":"36","author":"P Pirintr","year":"2012","unstructured":"Pirintr P, Chansaisakorn W, Trisiriroj M, Kalandakanond-Thongsong S, Buranakarl C. Heart rate variability and plasma norepinephrine concentration in diabetic dogs at rest. Vet Res Commun. 2012;36(4):207\u201314.","journal-title":"Vet Res Commun"},{"issue":"24","key":"3770_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/vr.100202","volume":"170","author":"MS Oliveira","year":"2012","unstructured":"Oliveira MS, Muzzi RA, Araujo RB, Muzzi LA, Ferreira DF, Nogueira R, et al. Heart rate variability parameters of myxomatous mitral valve disease in dogs with and without heart failure obtained using 24-hour Holter electrocardiography. Vet Rec. 2012;170(24):622.","journal-title":"Vet Rec"},{"issue":"7","key":"3770_CR24","doi-asserted-by":"publisher","first-page":"e02034","DOI":"10.1016\/j.heliyon.2019.e02034","volume":"5","author":"CG Carvalho","year":"2019","unstructured":"Carvalho CG, Bresler R, Zhi YX, Alshaer H, Granton JT, Ryan CM. Heart rate variability in pulmonary hypertension with and without sleep apnea. Heliyon. 2019;5(7):e02034.","journal-title":"Heliyon"},{"issue":"2","key":"3770_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jvim.15725","volume":"34","author":"C Reinero","year":"2020","unstructured":"Reinero C, Visser LC, Kellihan HB, Masseau I, Rozanski E, Clercx C, et al. ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. J Vet Intern Med. 2020;34(2):549\u201373.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"3770_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2460\/ajvr.2003.64.145","volume":"64","author":"Y Fujii","year":"2003","unstructured":"Fujii Y, Wakao Y. Spectral analysis of heart rate variability in dogs with mild mitral regurgitation. Am J Vet Res. 2003;64(2):145\u20138.","journal-title":"Am J Vet Res"},{"issue":"2","key":"3770_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1748-5827.1996.tb01941.x","volume":"37","author":"J Haggstrom","year":"1996","unstructured":"Haggstrom J, Hamlin RL, Hansson K, Kvart C. Heart rate variability in relation to severity of mitral regurgitation in Cavalier King Charles spaniels. J Small Anim Pract. 1996;37(2):69\u201375.","journal-title":"J Small Anim Pract"},{"issue":"2","key":"3770_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1590\/1678-41626097","volume":"66","author":"MS Oliveira","year":"2014","unstructured":"Oliveira MS, Muzzi RAL, Ara\u00fajo RB, Muzzi LAL, Ferreira DF, Silva EF. Heart rate variability and arrhythmias evaluated with Holter in dogs with degenerative mitral valve disease. Arq Bras Med Vet Zootec. 2014;66(2):425\u201332.","journal-title":"Arq Bras Med Vet Zootec"},{"issue":"1","key":"3770_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1939-1676.2011.00842.x","volume":"26","author":"CE Rasmussen","year":"2012","unstructured":"Rasmussen CE, Falk T, Zois NE, Moesgaard SG, Haggstrom J, Pedersen HD, et al. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease. J Vet Intern Med. 2012;26(1):76\u201384.","journal-title":"J Vet Intern Med"},{"issue":"4","key":"3770_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1538\/expanim.18-0030","volume":"67","author":"P Pirintr","year":"2018","unstructured":"Pirintr P, Limprasutr V, Saengklub N, Pavinadol P, Yapao N, Limvanicharat N, et al. Acute effect of ivabradine on heart rate and myocardial oxygen consumption in dogs with asymptomatic mitral valve degeneration. Exp Anim. 2018;67(4):441\u20139.","journal-title":"Exp Anim"},{"issue":"1","key":"3770_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/jvim.14885","volume":"32","author":"A Boswood","year":"2018","unstructured":"Boswood A, Gordon SG, Haggstrom J, Wess G, Stepien RL, Oyama MA, et al. Longitudinal analysis of Quality of Life, Clinical, Radiographic, echocardiographic, and laboratory variables in Dogs with Preclinical Myxomatous Mitral Valve Disease receiving Pimobendan or Placebo: the EPIC Study. J Vet Intern Med. 2018;32(1):72\u201385.","journal-title":"J Vet Intern Med"},{"issue":"6","key":"3770_CR32","first-page":"751","volume":"64","author":"D Mokra","year":"2013","unstructured":"Mokra D, Tonhajzerova I, Pistekova H, Visnovcova Z, Mokry J, Drgova A, et al. Short-term cardiovascular effects of selective phosphodiesterase 3 inhibitor olprinone versus non-selective phosphodiesterase inhibitor aminophylline in a meconium-induced acute lung injury. J Physiol Pharmacol. 2013;64(6):751\u20139.","journal-title":"J Physiol Pharmacol"},{"issue":"6","key":"3770_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","volume":"23","author":"C Atkins","year":"2009","unstructured":"Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23(6):1142\u201350.","journal-title":"J Vet Intern Med"},{"key":"3770_CR34","doi-asserted-by":"crossref","unstructured":"Bagardi M, Zamboni V, Locatelli C, Galizzi A, Ghilardi S, Brambilla PG. Management of chronic congestive heart failure caused by Myxomatous Mitral Valve Disease in Dogs: a narrative review from 1970 to 2020. Anim (Basel). 2022;12(2).","DOI":"10.3390\/ani12020209"},{"issue":"2","key":"3770_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1253\/circj.66.149","volume":"66","author":"TES Group","year":"2002","unstructured":"Group TES. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J. 2002;66(2):149\u201357.","journal-title":"Circ J"},{"issue":"4","key":"3770_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.5326\/0420249","volume":"42","author":"CW Lombard","year":"2006","unstructured":"Lombard CW, Jons O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249\u201361.","journal-title":"J Am Anim Hosp Assoc"},{"issue":"9","key":"3770_CR37","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/bph.13062","volume":"172","author":"M Nonaka","year":"2015","unstructured":"Nonaka M, Morimoto S, Murayama T, Kurebayashi N, Li L, Wang YY, et al. Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. Br J Pharmacol. 2015;172(9):2369\u201382.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"3770_CR38","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.amjcard.2007.01.032","volume":"99","author":"G Tacoy","year":"2007","unstructured":"Tacoy G, Balcioglu AS, Arslan U, Durakoglugil E, Erdem G, Ozdemir M, et al. Effect of metoprolol on heart rate variability in symptomatic patients with mitral valve prolapse. Am J Cardiol. 2007;99(11):1568\u201370.","journal-title":"Am J Cardiol"},{"issue":"1","key":"3770_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1515\/pjvs-2017-0021","volume":"20","author":"S Bogucki","year":"2017","unstructured":"Bogucki S, Noszczyk-Nowak A. Short-term heart rate variability in dogs with sick sinus syndrome or chronic mitral valve disease as compared to healthy controls. Pol J Vet Sci. 2017;20(1):167\u201372.","journal-title":"Pol J Vet Sci"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-023-03770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-023-03770-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-023-03770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:46:24Z","timestamp":1730310384000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-023-03770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3770"],"URL":"https:\/\/doi.org\/10.1186\/s12917-023-03770-6","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experimental protocol was approved by the Institutional Animal Care and Use Committee of the Faculty of Veterinary Science, Chulalongkorn University, Thailand <i>(<\/i>Approval protocol no. 1631067<i>)<\/i>. The Animals for Scientific Purposes Act, A.D. 2015 and the Ethical Principles and Guidelines for the Procedures on Animals for Scientific Purposes were followed with the consent of the owners to participate in the study. All reported methods are in accordance with the ARRIVE guidelines","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}